JTO Clinical and Research Reports: Editor-in-Chief Applications Invited | IASLC
The International Association for the Study of Lung Cancer (IASLC) invites applications for the position of Editor-in-Chief for JTO Clinical and Research Report …
Related Articles
Lung Cancer in Syria
Syria is a low-income country located on the eastern shores of the Mediterranean Sea basin in the Middle East. The area of Syria is 185,180…
The IASLC Lung Cancer Staging Project: Proposals for Revision of the Classification of Residual Tumor after Resection for the Forthcoming (9th) Edition of the TNM Classification of Lung Cancer
The goal of surgical resection is to completely remove a cancer; it is useful to have a system to describe how well this was accomplished.…
Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC
EGFR accounts for 15% to 50% of nonsquamous, advanced NSCLC. Among various EGFR tyrosine kinase inhibitors (TKIs) designed to target sensitizing mutations (exon 19 deletion,…
Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC
EGFR accounts for 15% to 50% of nonsquamous, advanced NSCLC. Among various EGFR tyrosine kinase inhibitors (TKIs) designed to target sensitizing mutations (exon 19 deletion,…
Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR+ NSCLC
“Don’t be afraid to give up the good to go for the great.”John D. Rockefeller
Five-Year Survival Outcomes After Carbon-Ion Radiotherapy for Operable Stage I NSCLC: A Japanese National Registry Study (J-CROS-LUNG)
The standard therapy for stage I NSCLC is surgery, but some operable patients refuse this option and instead undergo radiotherapy. Carbon-ion radiotherapy (CIRT) is a…
Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (RATIONALE-312): a Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial
Extensive-stage small cell lung cancer (ES-SCLC) prognosis remains poor. The phase 3 RATIONALE-312 study aimed to evaluate efficacy and safety of tislelizumab plus chemotherapy as…
Lung Cancer in Switzerland
Currently, 8.7 million people live in Switzerland—a number that has more than doubled in the past 100 years. In the same time, the population has…
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming 9th edition of the TNM Classification of Lung Cancer
This study analyzed all metastatic categories of the current tumor, node, and metastasis (TNM) classification of non-small cell lung cancer to propose modifications of the…